A trial points to a less restrictive path for potassium management
For people receiving maintenance hemodialysis, managing high blood potassium is often inseparable from managing food. Dietary potassium restriction can be an important part of care for hyperkalemia, but it can also add a persistent burden to everyday decisions about meals and nutrition.
New clinical-trial results suggest that sodium zirconium cyclosilicate, or SZC, may help reduce that burden when used alongside nutritional counseling and regular monitoring. The findings, scheduled for presentation at ASN Kidney Week 2026, come from a multicenter randomized study of outpatients receiving dialysis three times a week.
The study does not argue that dietary guidance can be abandoned. Its investigators instead frame the result as a potential way to give patients more flexibility while maintaining potassium control. That distinction matters: the central question is not simply whether a laboratory value falls, but whether treatment can make the work of living with kidney disease less demanding.
How the eight-week study was designed
Participants were receiving thrice-weekly maintenance hemodialysis and had pre-dialysis serum potassium levels from 5.5 to less than 6.5 mEq/L. They were randomly assigned to one of two approaches for eight weeks: SZC plus standardized nutritional counseling, or standardized nutritional counseling alone.
The main analysis included 183 patients. According to the reported results, patients receiving SZC alongside counseling showed a greater improvement in quality of life related specifically to dietary potassium restriction than those who received counseling alone. The SZC group also had more effective reductions in pre-dialysis serum potassium.
A practical difference emerged in the need for rescue treatment. No patient in the SZC group required rescue treatment over the eight-week period. In the control group, 25 of 92 patients did. That result is notable because it combines two outcomes patients and clinicians must manage at once: keeping potassium under control and avoiding additional interventions when control is not achieved.
Quality of life is part of the clinical result
Hyperkalemia treatment is often evaluated through serum potassium measurements. The researchers argue that this alone is incomplete. Dietary restrictions can shape social routines, shopping, cooking and food choices, making the burden of treatment a meaningful outcome in its own right.
In exploratory analyses, the investigators observed increased fruit intake without an increase in total dietary potassium intake. They also reported improvements in several areas of kidney disease-related quality of life. The trial did not report serious treatment-related adverse events or deaths.
Those findings do not establish that every patient on dialysis should change their diet or begin SZC. The study was limited to eight weeks, and the results described are trial findings being presented at a medical meeting. But they do highlight a patient-centered way of judging therapy: successful management should address both biochemical control and the day-to-day consequences of achieving it.
Why nutrition counseling remains central
The investigators emphasized that individualized dietary assessment, regular potassium monitoring and attention to overall nutritional quality remain essential. That caution is important because the reported benefit came from adding SZC to standardized counseling, not from replacing clinical nutrition support with a medication.
Dietary potassium management can be especially complex for people on dialysis because foods are not merely sources of a single nutrient. A restriction intended to lower potassium can affect the variety and quality of a person’s diet. The exploratory finding on fruit intake therefore offers a useful signal, but it should be interpreted in the context of the study’s monitoring and counseling structure.
The trial also illustrates why patient-reported outcomes deserve a more prominent place in kidney-disease research. A therapy may lower a clinical measurement, yet still leave people with a regimen that is difficult to sustain. Conversely, a treatment that safely reduces the daily friction of dietary management could have value beyond its effect on an individual blood test.
What comes next
The researchers’ conclusion is deliberately measured. SZC may offer a patient-centered benefit beyond lowering serum potassium when it is added to nutritional counseling and routine monitoring. Longer-term evidence and fuller reporting will be needed to clarify how durable the quality-of-life effects are and which patients are most likely to benefit.
For now, the results provide evidence that a medication strategy can be assessed through more than potassium numbers. In this study, better control was accompanied by a lower reported burden from dietary restriction and no need for rescue treatment among patients assigned to SZC. That combination could be meaningful for people whose treatment plans require continual attention to both dialysis schedules and food choices.
The message from the trial is not that restrictions no longer matter. It is that care may be improved when clinicians measure whether the plan is workable in ordinary life as well as effective in the clinic.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
